An increased incidence of complications of atherosclerosis has been noted in cancer survivors. The aim of the present study was to evaluate, in patients with breast carcinoma, the effect of antracycline-based chemotherapy on carotid intima-media thickness (IMT), myocardial perfusion, assessed by single-photon emission tomography (SPECT) and laboratory parameters associated with the risk of atherosclerosis. Thirty-six patients with breast cancer were evaluated before and after anthracycline-based chemotherapy. Retinol, alpha-tocopherol, glycosylated hemoglobin and urinary neopterin were measured by high-performance liquid chromatography. Peripheral blood cell count, D-dimers, fibrinogen, antithrombin, glucose, magnesium, creatinine, uric acid, albumin, C-reactive protein, lipoprotein (a), cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, homocysteine, urinary albumin and N-acetyl-beta-D-glucosaminidase (NAG) were determined with routine methods. No significant differences were observed between patients and 16 controls. Compared to the measurement before the start of therapy, peripheral blood leukocyte and platelet count, hemoglobin, creatinine, HDL cholesterol, retinol, albumin, urinary albumin and NAG decreased, and total cholesterol, LDL cholesterol, triglycerides, neopterin and mean IMT increased significantly after the treatment. Of the 36 patients who had SPECT after treatment, perfusion defects were noted only in two cases, including the patient who had perfusion defects at baseline examination and a patient who did not have a baseline SPECT. In conclusion, a significant increase in carotid IMT, total cholesterol, LDL cholesterol, triglycerides and urinary neopterin and a decrease of peripheral blood leukocyte and platelet counts, hemoglobin, creatinine, HDL cholesterol, retinol, albumin and NAG were observed after the treatment.

Department of Oncology and Radiotherapy Charles University School of Medicine Hradec Kralove Czech Republic

Zobrazit více v PubMed

Adv Intern Med. 2000;45:391-418 PubMed

Clin Chem. 2009 Jun;55(6):1135-46 PubMed

Ann Intern Med. 1994 Jan 15;120(2):104-10 PubMed

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):508-16 PubMed

Eur J Cancer. 2005 May;41(7):1026-30 PubMed

J Clin Oncol. 2005 Dec 20;23(36):9130-7 PubMed

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1023-8 PubMed

Tex Heart Inst J. 2009;36(3):205-13 PubMed

J Intern Med. 2005 Aug;258(2):124-32 PubMed

J Clin Oncol. 2004 Feb 15;22(4):640-7 PubMed

J BUON. 2006 Oct-Dec;11(4):505-9 PubMed

Am J Cardiol. 2002 Oct 15;90(8):827-32 PubMed

J Clin Oncol. 2000 Apr;18(8):1725-32 PubMed

J Clin Oncol. 2003 Apr 15;21(8):1513-23 PubMed

Am Heart J. 2004 Jun;147(6):1093-9 PubMed

Scand J Clin Lab Invest. 1995 Apr;55(2):149-52 PubMed

Br J Nutr. 2005 Feb;93(2):153-74 PubMed

Anticancer Res. 2008 Jul-Aug;28(4C):2389-96 PubMed

Cancer. 2007 Feb 15;109(4):650-7 PubMed

Anticancer Res. 2009 Nov;29(11):4813-20 PubMed

J Med. 1995;26(5-6):221-33 PubMed

Circulation. 2002 Dec 3;106(23):2925-9 PubMed

Circulation. 1998 Feb 17;97(6):535-43 PubMed

Eur J Cancer. 2004 Mar;40(5):701-6 PubMed

Stroke. 2002 Nov;33(11):2581-6 PubMed

Am J Cardiol. 2009 Nov 15;104(10):1383-8 PubMed

Vasc Med. 2006 Nov;11(3):201-11 PubMed

Clin Exp Immunol. 1995 Oct;102(1):217-23 PubMed

Int J Radiat Oncol Biol Phys. 1978 Sep-Oct;4(9-10):895-906 PubMed

N Engl J Med. 2005 Apr 21;352(16):1685-95 PubMed

J Exp Clin Cancer Res. 2004 Dec;23(4):579-84 PubMed

Breast Cancer Res Treat. 1996;40(3):265-70 PubMed

Clin Nutr. 2002 Apr;21(2):161-4 PubMed

J Clin Endocrinol Metab. 2006 Nov;91(11):4433-7 PubMed

J Clin Oncol. 2006 Jun 20;24(18):2779-85 PubMed

Anticancer Res. 2009 Aug;29(8):3337-46 PubMed

Ann Clin Biochem. 2004 Mar;41(Pt 2):138-41 PubMed

Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor